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Introduction
Cancer is the leading and second leading cause of 
death in developed and developing countries, respectively 
(WHO, 2008). The incidence and mortality of cancers are 
burgeoning as a result of population age and growth along 
with changes in lifestyles including smoking, physical 
inactivity, etc. in economically developing parts of the 
world (Jemal et al., 2011). Colorectal and cervical cancers 
are among the most frequently encountered cancers in 
humans. Colorectal cancer is the third most commonly 
diagnosed cancer in man and the second in woman 
globally. Cervical cancer is the third most commonly 
diagnosed cancer and the fourth leading cause of cancer 
death in females globally. More than 85% of these cases 
and deaths are found to occur in developing countries 
(Ferlay et al., 2010). A combination of late clinical 
presentation of symptoms and lack of adequate access to 
timely and standard treatment limits the cancer survival 
trends in developing countries (Jemal et al., 2011).
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Abstract
 Background: Recent attention on chemotherapeutic intervention against cancer has been focused on 
discovering and developing phytochemicals as anticancer agents with improved efficacy, low drug resistance 
and toxicity, low cost and limited adverse side effects. In this study, we investigated the effects of Curcuma 
C20-dialdehyde on growth, apoptosis and cell cycle arrest in colon and cervical cancer cell lines. Materials and 
Methods: Antiproliferative, apoptosis induction, and cell cycle arrest activities of Curcuma C20-dialdehyde 
were determined by WST cell proliferation assay, flow cytometric Alexa fluor 488-annexin V/propidium iodide 
(PI) staining and PI staining, respectively. Results: Curcuma C20 dialdehyde suppressed the proliferation of 
HCT116, HT29 and HeLa cells, with IC50 values of 65.4±1.74 µg/ml, 58.4±5.20 µg/ml and 72.0±0.03 µg/ml, 
respectively, with 72 h exposure. Flow cytometric analysis revealed that percentages of early apoptotic cells 
increased in a dose-dependent manner upon exposure to Curcuma C20-dialdehyde. Furthermore, exposure to 
lower concentrations of this compound significantly induced cell cycle arrest at G1 phase for both HCT116 and 
HT29 cells, while higher concentrations increased sub-G1 populations. However, the concentrations used in this 
study could not induce cell cycle arrest but rather induced apoptotic cell death in HeLa cells. Conclusions: Our 
findings suggest that the phytochemical Curcuma C20-dialdehyde may be a potential antineoplastic agent for 
colon and cervical cancer chemotherapy and/or chemoprevention. Further studies are needed to characterize 
the drug target or mode of action of the Curcuma C20-dialdehyde as an anticancer agent. 
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Chemotherapy is one of most practiced approaches in 
advanced carcinogenesis as well as metastatic condition 
and also an adjuvant therapy for many cancers at 
present. However, clinical application of this approach 
often features serious challenges involving toxicity, 
side-effects and resistance development by cancer cells 
which underscore the desperate need for relatively non-
toxic natural products (Pan and Ho, 2008). Currently, 
several purified natural products and their derivatives 
with immense pharmacological and biological properties 
have been discovered as potential candidates for cancer 
chemotherapy. The natural products preferentially function 
in multiple mechanistic pathways and overcome chemo-
resistance in tumors with cumulative actions (Saha and 
Khuda-Bukhsh, 2013). The tremendous ability of natural 
products to act as effective scaffolds and bind bewildering 
types of protein domains and folding motifs makes 
them effective modulators of various cellular processes, 
contributing to immune responses, signal transduction, 
cell division and apoptosis (Peczuh and Hamilton, 2000). 
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Medicinal plants are important sources of 
chemopreventive and therapeutic agents for a wide variety 
of solid and hematological cancers. Now-a-days, Curcuma 
species is receiving greater importance across the globe 
as a potential source of new drug(s) to combat a variety 
of ailments as the species contain a lot of compounds 
conferring anti-inflammatory, antioxidative, antimicrobial, 
antirheumatic, antivenomous, antiviral, antihepatotoxic as 
well as anticancerous properties. Over last few decades, 
researchers have devoted extensive interests in exploring 
the biological and pharmacological activities of Curcuma, 
especially the cultivated species (Sasikumar, 2005). 
Among various phytochemicals, curcuminoids which 
are the biologically active principles from Curcuma 
species play vital roles in the control of rheumatism, 
carcinogenesis and oxidative stress-related pathogenesis 
(Mors et al., 2000; Sasikumar, 2005). 
Curcumin (diferuloylmethane),  one of the 
curcuminoids, is a phenolic compound derived from 
the rhizomes of turmeric (Curcuma longa L.). It has 
been used as herbal medicine for treatment of cancers, 
snake bites and many other ailments for centuries 
(Somasundaram, 2002). Curcumin is highly popular 
because of its chemopreventive property against human 
cancers (Aggarwal et al., 2003, Guo et al., 2013). There is 
convincing evidence in preclinical model and in vitro assay 
that curcumin has growth inhibitory effect on numerous 
cancer cells such as breast cancer (Ramachandran et al., 
2002), oesophageal cancer (O’Sullivan-Coyne et al., 
2009), colon cancer (Milacic et al., 2008), bile duct cancer 
(Prakobwong et al., 2011) and gall bladder cancers (Liu 
et al., 2013). 
In addition, curcumin has effects on several 
different targets including transcription factors, growth 
regulators, adhesion molecules, angiogenesis regulators 
and cellular signaling molecules (Aggarwal et al., 
2003). It may have chemopreventive potential against 
cholangiocarcinogenesis through activation of multiple 
cell signaling pathways associated with tumor promotion 
and progression (Prakobwong et al., 2011). Preclinical 
efficacy, less toxicity as well as side effects and availability 
of curcumin as natural product are the compelling factors 
to incorporate this agent in human clinical trial for 
chemopreventive potential.
Curcuma zedoaroides A. Chaveerach & T. Tanee, locally 
known as “Wan-Phaya-Ngoo-Tua-Mia” in Thai, is a new 
plant in the genus Curcuma (Zingiberaceae). The acetone 
extract of Curcuma zedoaroides rhizomes contained 
a Curcuma C20-dialdehyde, 2-[2-(5,5,8a-trimethyl-2-
methylene-decahydro-naphthalen-1-yl)-ethylidene]-
succinaldehyde, as a major component with antivenomous 
effect (Lattmann et al., 2010). Although numerous studies 
documented chemopreventive potential of curcumin 
against a wide variety of tumors, anticancer impacts of 
the Curcuma C20-dialdehyde remain to be elucidated 
extensively. So the aims of the present study were to 
evaluate antiproliferative activity of Curcuma C20-
dialdehyde and to unravel the underlying mechanism(s) of 
its tumor growth inhibition. Our results demonstrated that 
Curcuma C20-dialdehyde inhibited the growth of colon 
and cervical cancer cells by induction of apoptosis and 
inhibition of cell cycle progression. We believe that this 
is the first work that shows the antiproliferative activity 
and underlying mechanisms of Curcuma C20-dialdehyde 
in colon and cervical cancer cell lines.
Materials and Methods
Reagents and medium 
Curcuma C20-dialdehyde was prepared as previously 
described (Lattmann et al., 2010). Culture medium 
RPMI-1640 and its supplements including antibiotics 
and fetal bovine serum were purchased from Gibco-BRL, 
Invitrogen, Basle, Switzerland. WST-8 cell Proliferation 
Assay Kit was purchased from Bio Vision, Mountain View, 
CA, USA. Vybrant Apoptosis Assay Kit #2 was purchased 
from Molecular Probes, Invitrogen Corporation, Carlsbad, 
CA, USA. Propidium Iodide (PI) and RNase A was 
purchased from Sigma, Dublin, Ireland. Curcuma C20 
dialdehyde was dissolved in dimethyl sulfoxide (DMSO) 
(Sigma, Dublin, Ireland). The final concentration of 
DMSO was maintained below 0.5% (v/v) in treatment 
groups and also in corresponding control. For apoptosis 
analysis, 10 µg/ml of camptothecin (Sigma, Dublin, 
Ireland) was used as positive control. 
Cell lines and culture condition
Human colorectal carcinoma cell line (HCT116) 
was collected from Dr. Osamu Tetsu (University of 
California, San Francisco), human colon adenocarcinoma 
cell line (HT29 cells) and human cervical carcinoma cell 
line (HeLa cells) were collected from National Cancer 
Institute, Bangkok, Thailand. Cells were cultured in 
RPMI-1640 medium containing 10% heat- inactivated 
fetal bovine serum, a mixture of penicillin (100 U/ml) 
and streptomycin (100 µg/ml), and incubated at 37ºC in 
a humidified atmosphere with 5% CO2. 
Antiproliferative activity assay
Antiproliferative activity was assayed by using a WST-
8 Cell Proliferation Assay Kit (BioVision, Mountain View, 
CA, USA) in accordance with manufacturer’s instructions. 
Briefly, cells at a density of 8×103 cells/well were seeded 
onto 96-well plates in triplicate and allowed for 24 h for 
attachment. After 24 h, cells were exposed to increasing 
concentrations of Curcuma C20-dialdehyde for 24, 48 and 
72 h. At the end of indicated time, WST reagent was added 
to cultures and incubated for 90 min at 37ºC. Tetrazolium 
salt was converted into formazan by enzyme-catalyzed 
reduction in viable cells. Absorbance (A) of formazan 
was measured at 415 nm with a microtiter plate reader 
(Bio-Rad Laboratories, Hercules, CA, USA) while 655 nm 
was used as a reference wavelength. The number of viable 
cells is corresponding to the production of formazan. Cell 
viability was calculated and expressed as percentages by 
the following equation:
% Cell viability = [Sample A/Control A] x 100
Apoptosis analysis by Flow cytometry
Apoptosis induction of HCT116, HT29 and HeLa 
cells was evaluated with flow cytometer using the Alexa 
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Fluor 488-Annexin V apoptosis detection kit following the 
manufacturer’s instructions. Briefly, cells (2.5×105 cells/
ml) were seeded in a 5.4-cm culture dish and incubated 
for 24 h. Cells were treated with three concentrations of 
Curcuma C20-dialdehyde (25, 50 and 100 µg/ml) for 
24 h. After 24 h of exposure, cells were harvested by 
trypsinization, washed with cold PBS and centrifuged 
(3,000 rpm for 3 min). Then, pellet of cells was re-
suspended and diluted in the Annexin-binding buffer to a 
number of 105 cells per assay, and subsequently incubated 
with Alexa Fluor 488-Annexin V and Propidium iodide 
(PI) for 15 min at room temperature. After the incubation, 
cells were subjected to be analyzed by a Beckman 
Coulter Cytomics FC500 MPL flow cytometry (Beckman 
Coulter, Maimi, FL, USA). The flow cytometric results 
on apoptosis were correlated with that of a conventional 
cell count technique using a fluorescence microscope.
Analysis of cell cycle profile by Flow cytometry
To analyze cell cycle profiles, HCT116, HT29 and 
HeLa cells were seeded at the density of 2.5×105 cells/
ml in a 5.4-cm culture dish and allowed for 24 h. Cells 
were then exposed to three concentration of Curcuma 
C20-dialdehyde (25, 50 and 100 µg/ml) for 24 h. After 
exposure, cells were harvested, washed with PBS, 
centrifuged (3,000 rpm for 3 min) and fixed with 70% 
cold ethanol at 4°C. After 1 h-fixation, cells were washed 
with PBS twice and incubated with 0.5 mg/ml RNaseA 
(Sigma, Dublin, Ireland) for 1 h to destroy double stranded 
RNA. Lastly, Propidium iodide (50 µg/ml) in PBS solution 
was added to stain nuclear DNA in subdued light for 40 
min at room temperature. The DNA histogram reflecting 
the percentages of cells at different cell cycle phases 
was determined by using a Cytomics FC500 MPL flow 
cytometrer (Beckman Coulter, Maimi, FL, USA).
Statistical analysis
All experiments were repeated separately at least 
three times. Data were presented as means±SD for three 
separate experiments. Statistical differences between 
sample-treated and solvent-treated cells were determined 
using one-way ANOVA with Duncan’s post hoc test. The 
criterion for consideration of statistical significance was 
set at p<0.05.
Results 
Effects of Curcuma C20-dialdehyde on proliferation of 
HCT116, HT29 and HeLa cells
To evaluate the effect of Curcuma C20-dialdehyde 
on cancer cell growth, its antiproliferative activity was 
determined in both colon cancer cell lines (HCT116 and 
HT29 cells) and cervical cancer cell line (HeLa cells). 
Curcuma C20-dialdehyde exhibited antiproliferative 
activity against all three cancer cell lines tested. As 
shown in Figure 2, cell growth was significantly (p<0.05) 
inhibited by Curcuma C20-dialdehyde in a dose- and 
time-dependent manner. Cellular sensitivities measured 
as IC50 (concentration required to decrease cell viability 
50%) are presented in Figure 2.
Effects of Curcuma C20-dialdehyde on apoptosis 
induction in HCT116, HT29 and HeLa cells
The flow cytometry results revealed that Curcuma 
C20-dialdehyde induced apoptosis of all cancer cells 
tested in a dose-dependent manner (Figure 3). The early 
apoptosis was evidenced from Alexa Fluor 488-Annexin 
V positive and PI negative staining. However, late 
apoptosis was detected by both Alexa Fluor 488-Annexin 
Figure 2. Effect of Curcuma C20-dialdehyde on Antiprolifertive Activity of HCT116, HT29 and HeLa Cells. 
HCT116 (A), HT29 (B) and HeLa cells (C) were treated with increasing concentration of Curcuma C20-dialdehyde for 24, 48 and 
72 h, and analyzed by WST-8 Cell Proliferation Assay. Cell viability was calculated as percentage. Data were expressed as mean±SD 
of three individual experiments
Figure 1. trans-Curcuma C20-dialdehyde CD; 
2-[2-(5,5,8a-trimethyl-2-methylene-decahydro-
naphthalen-1-yl)-ethylidene]-succinaldehyde 
(Lattmann et al., 2010)
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V and PI positive staining. The percentages of apoptosis 
increased from 3.60±0.21% to 42.40±2.14% in HCT116, 
from 2.40±1.98% to 54.50±3.80% in HT29 and from 
4.90±0.45% to 43.80±2.76% in HeLa cells upon 
24 h-exposure to Curcuma C20-dialdehyde at the 
concentration of 100 µg/ml. The observed morphological 
changes due to apoptosis induction after treatment with 
different concentrations are presented in Figure 4.
 
Effects of Curcuma C20-dialdehyde on cell cycle 
progression in HCT116, HT29 and HeLa cells
As presented in Figure 5A and 5D, low concentration 
(25 µg/ml) of Curcuma C20-dialdehyde increased 
the percentages of G1 phase in HCT116 cells from 
75.3±0.71% to 87.00±1.84% and moderate concentration 
(50 µg/ml) induced the cell cycle arrest at G2/M phase 
with more sub-G1 fraction (20.75±1.32%). However, 
the highest concentration treatment in HCT116 cells 
caused more cell death evidenced by the presence of more 
sub-G1 fraction (52.55±2.3%). The treatment of HT29 
cells with 50 µg/ml of Curcuma C20-dialdehyde resulted 
in cell cycle arrest at G1 phases (82.45±1.41%) (Figure 
5B and 5E). In addition, the sub-G1 fraction gradually 
Figure 3. Effect on Induction of Apoptosis by Curcuma C20-dialdehyde in HCT116, HT29 and HeLa Cells. (A-C) 
Representative dot plots display the apoptotic cell death of HCT116, HT29, and HeLa cells. Cells were treated with 0, 25, 50 and 
100 µg/ml of Curcuma C20-dialdehyde for 24 h, labeled with Alexa Fluor 488-Annexin V and Propidium iodide (PI) and analyzed 
by flow cytometer. Cells treated with solvent and Camptothecin (10 µg/ml) were used as negative and positive control, respectively. 
(D-F) Bar graphs show the summarized data (mean±SD) from three independent experiments performed in duplicate. *p<0.05 for 
comparison between drug and control treatments
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Figure 4. Morphological Changes Leading to Apoptosis 
by Curcuma C20-dialdehyde in HCT116, HT29 and 
HeLa Cells. HCT116 (A-C), HT29 (D-F) and HeLa (G-I) cells 
were treated with 0, 50, 100 µg/ml of Curcuma C20-dialdehyde, 
respectively, for 24 h. Morphological changes including 
shrinkage of cell, membrane blebbing, fragmentation of cells 
etc. upon exposure to Curcuma C20-dialdehyde were observed 
under microscope (Olympus 20X) and photographed
A! B! C!
D! E! F!
G! H! I!
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increased with increasing concentrations of Curcuma C20-
dialdehyde in HT29 cells. The treatments with Curcuma 
C20-dialdehyde at the concentrations used in this study did 
not block the cell cycle progression in HeLa cells (Figure 
5C and 5F). However, the increased sub-G1 fractions 
were observed in HeLa cells treated with the increasing 
concentrations of Curcuma C20-dialdehyde. Our results 
indicated that the ability of Curcuma C20-dialdehyde to 
induce cell cycle arrest is depending on the cellular model 
and concentrations.
Discussion
We, to the best of our knowledge, are the first who 
studied the anticancer effects of Curcuma C20-dialdehyde 
on cancer cell lines. Our study demonstrated that Curcuma 
C20-dialdehyde had the potential for inhibition of cancer 
Figure 5. Effect on Induction of Cell Cycle Arrest by Curcuma C20-dialdehyde in HCT116, HT29 and HeLa 
Cells. (A-C) Representative DNA histograms on cell cycle profile of HCT116, HT29 and HeLa cells. Histograms showed a number 
of cells per channel (vertical axis) vs DNA content (horizontal axis). Cells were treated with 0, 25, 50 and 100 µg/ml of Curcuma 
C20-dialdehyde for 24 h, stained with Propidium iodide and analyzed using flow cytometry. (D-F) Bar graphs show summarized 
data (mean±SD) for three independent experiments on proportion of cells in different phases of cell cycle for HCT116, HT29 and 
HeLa cells, respectively. *p<0.05 for comparison between drug and control treatments. 
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cell growth in vitro. The antiproliferative effect posed 
by Curcuma dialdehyde was time- and dose-dependent 
for both colon cancer (HCT116, HT29) and cervical 
cancer (HeLa) cell lines. In line with our findings, some 
researchers also reported antiproliferative activity of some 
natural compound from Curcuma sp. and other plants. It 
was reported that curcumin had potent dose-dependent 
antiproliferative effects in cholangiocarcinoma cells 
(Prakobwong et al., 2011) and colorectal carcinoma LoVo 
cells (Guo et al., 2013), human osteosarcoma (HOS) cells 
(Lee et al., 2009). Some oils of Curcuma species were 
known to confer growth inhibitory impacts on several 
cancer cell lines. Curcuma zedoaria oil had a significant 
inhibitory effect on the proliferation of SGC-7901 cells 
and could induce apoptosis (Guo SB et al., 2013). Essential 
oil of Curcuma wenyujin (CWO) was found to inhibit the 
growth of HepG2 cells in a dose-dependent fashion by 
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inducing a cell cycle arrest at S/G2 (Xiao et al., 2008). 
To investigate the mechanisms by which Curcuma C20-
dialdehyde confers growth inhibitory effect in cancer 
cells, we assessed cell cycle phase distribution and 
apoptosis induction in vitro. Our results demonstrated 
that Curcuma C20-dialdehyde could induce apoptosis of 
all cancer cells tested in this study in a dose-dependent 
manner, indicating possibility of curative and preventive 
windows. Among the cell lines studied, HT29 was found 
to be more responsive in apoptosis induction to Curcuma 
C20-dialdehyde where more than 50% cells underwent 
apoptosis with 100 µg/ml of the drug. Furthermore, this 
compound also induced the cell cycle arrest at G1 phase 
of cell cycle for HCT116 cells and HT29 cells while 
there had not been any evidence of cell cycle arrest in 
HeLa cells. Exposure to low level of Curcuma C20-
dialdehyde showed a substantial delayed at G0/G1 phase 
in HCT116 cells where moderate concentration arrested 
cell cycle at the same phase in HT29 cells. Increasing 
percentages of sub-G1 for all three cell lines with the 
higher concentrations indicated more cell death, which 
coincided with apoptosis induction. So, it was evident 
from our study that concentrations and types of cell lines 
had played the decisive role in underlying mechanisms 
of growth inhibition. Variations in the extent of DNA 
damage and ability of damage repair mechanisms are the 
controlling factors for determining the fates of neoplastic 
cells. Whether or not Curcuma C20-dialdehyde will be 
effective in vivo, it needs further investigation. Our results 
for mechanism of growth inhibition were corroborated 
by several previous research findings. Live/Dead assay 
showed that curcumin significantly increased apoptotic 
cell death in CCA cells in a dose-dependent manner 
(Prakobwong et al., 2011). Guo et al. (2013) reported that 
curcumin induced the cell cycle arrest of LoVo cells at 
the S phase and apoptosis of colorectal carcinoma LoVo 
cells in a dose-dependent manner through a mitochondria-
mediated pathway. It has also been reported that curcumin 
caused death of human osteosarcoma (HOS) cells by 
blocking cells successively in G1/S and G2/M phases and 
inducing apoptosis by activating the caspase-3 pathway 
(Lee et al., 2009). Curcuma zedoaria oil induced inhibition 
of SGC-7901 cell proliferation by retardation of G0/
G1 phase (Guo et al., 2013). Extensive research over a 
few decades has contributed in identification of various 
molecular targets that can potentially be used both for the 
prevention and treatment of cancer. The active principles 
identified in fruit and vegetables modulate various 
cell signaling pathways pertaining to carcinogenesis 
(Aggarwal and Shishodia, 2006). Epidemiological 
studies have consistently shown that dietary intakes of 
phytochemicals with fruits and vegetables are strongly 
associated with reduced risk of developing cancers (Liu, 
2004). Considering the findings of the present study and 
related discussions, we can envisage Curcuma C20-
dialdehyde as chemopreventive agent and suggest the 
possibility of developing it as an anticancer compound 
for cancer prevention and treatment in the future.
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